Tarsus Pharmaceuticals Inc
TARS41.468USD
+0.658+1.61%
交易中 （美東）報價延遲15分鐘
1.74B總市值
虧損本益比TTM
關於 Tarsus Pharmaceuticals Inc 公司
Tarsus Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司。該公司專注於治療藥物的開發和商業化，從眼部護理開始。該公司的主要候選產品 XDEMVY 是一種洛蒂蘭眼科溶液，可針對並根除蠕形蟎眼瞼炎的根本原因——蠕形蟎感染。XDEMVY 的活性藥物成分 (API) 洛蒂蘭通過抑制寄生蟲特異性 γ-氨基丁酸門控氯離子通道來麻痹和根除蟎蟲和其他寄生蟲。該公司正在研究其候選產品的開發，以解決具有高度未滿足醫療需求的目標疾病，其中包括用於治療瞼板腺疾病 (MGD) 的 TP-03、用於治療紅斑痤瘡的新型凝膠製劑 TP-04 和用於預防萊姆病和減少社區瘧疾的新型口服制劑 TP-05。
公司簡介
公司代碼TARS
公司名稱Tarsus Pharmaceuticals Inc
上市日期Oct 16, 2020
CEOMr. Bobak (Bobby) Azamian, M.D., Ph.D.
員工數量323
證券類型Ordinary Share
年結日Oct 16
公司地址15440 Laguna Canyon Road
城市IRVINE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編92618
電話19494099820
網址https://www.tarsusrx.com/
公司代碼TARS
上市日期Oct 16, 2020
CEOMr. Bobak (Bobby) Azamian, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. William J. Link, Ph.D.
Dr. William J. Link, Ph.D.
Independent Director
Independent Director
180.89K
+1.89%
Dr. Seshadri Neervannan, Ph.D.
Dr. Seshadri Neervannan, Ph.D.
Chief Operating Officer
Chief Operating Officer
79.68K
+23.03%
Dr. Bryan Wahl, M.D., J.D.
Dr. Bryan Wahl, M.D., J.D.
General Counsel, Secretary
General Counsel, Secretary
49.09K
+24.08%
Mr. Aziz Mottiwala
Mr. Aziz Mottiwala
Chief Commercial Officer
Chief Commercial Officer
47.56K
-26.90%
Ms. Dianne C. Whitfield
Ms. Dianne C. Whitfield
Chief Human Resources Officer
Chief Human Resources Officer
44.38K
+37.80%
Mr. Jeffrey S. (Jeff) Farrow
Mr. Jeffrey S. (Jeff) Farrow
Chief Financial Officer and Chief Strategy Officer
Chief Financial Officer and Chief Strategy Officer
36.70K
+63.63%
Ms. Wendy L. Yarno
Ms. Wendy L. Yarno
Lead Independent Director
Lead Independent Director
13.70K
+32.37%
Dr. Bhaskar Chaudhuri, Ph.D.
Dr. Bhaskar Chaudhuri, Ph.D.
Independent Director
Independent Director
8.70K
+62.62%
Dr. Andrew Goldberg, M.D.
Dr. Andrew Goldberg, M.D.
Independent Director
Independent Director
--
--
Dr. Elizabeth Yeu, M.D.
Dr. Elizabeth Yeu, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. William J. Link, Ph.D.
Dr. William J. Link, Ph.D.
Independent Director
Independent Director
180.89K
+1.89%
Dr. Seshadri Neervannan, Ph.D.
Dr. Seshadri Neervannan, Ph.D.
Chief Operating Officer
Chief Operating Officer
79.68K
+23.03%
Dr. Bryan Wahl, M.D., J.D.
Dr. Bryan Wahl, M.D., J.D.
General Counsel, Secretary
General Counsel, Secretary
49.09K
+24.08%
Mr. Aziz Mottiwala
Mr. Aziz Mottiwala
Chief Commercial Officer
Chief Commercial Officer
47.56K
-26.90%
Ms. Dianne C. Whitfield
Ms. Dianne C. Whitfield
Chief Human Resources Officer
Chief Human Resources Officer
44.38K
+37.80%
Mr. Jeffrey S. (Jeff) Farrow
Mr. Jeffrey S. (Jeff) Farrow
Chief Financial Officer and Chief Strategy Officer
Chief Financial Officer and Chief Strategy Officer
36.70K
+63.63%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月23日 週五
更新時間: 5月23日 週五
持股股東
股東類型
持股股東
持股股東
佔比
RTW Investments L.P.
7.89%
BlackRock Institutional Trust Company, N.A.
6.74%
Paradigm BioCapital Advisors LP
6.21%
Jennison Associates LLC
5.87%
Tang Capital Management, LLC
5.84%
Other
67.44%
持股股東
持股股東
佔比
RTW Investments L.P.
7.89%
BlackRock Institutional Trust Company, N.A.
6.74%
Paradigm BioCapital Advisors LP
6.21%
Jennison Associates LLC
5.87%
Tang Capital Management, LLC
5.84%
Other
67.44%
股東類型
持股股東
佔比
Investment Advisor
32.82%
Hedge Fund
30.26%
Investment Advisor/Hedge Fund
28.62%
Research Firm
10.92%
Private Equity
4.88%
Individual Investor
3.36%
Pension Fund
0.34%
Bank and Trust
0.23%
Insurance Company
0.03%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
401
46.02M
109.53%
-4.01M
2025Q1
407
48.50M
115.53%
-3.34M
2024Q4
378
44.81M
116.78%
-6.00M
2024Q3
339
47.74M
124.97%
+1.40M
2024Q2
315
44.21M
116.20%
+181.38K
2024Q1
291
44.53M
119.96%
+4.60M
2023Q4
241
35.50M
106.12%
-146.85K
2023Q3
226
34.34M
108.40%
+5.84M
2023Q2
202
25.92M
97.99%
-1.52M
2023Q1
186
24.53M
93.13%
-2.70M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RTW Investments L.P.
3.32M
7.89%
+79.48K
+2.46%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
6.74%
-82.65K
-2.84%
Mar 31, 2025
Paradigm BioCapital Advisors LP
2.61M
6.21%
+78.30K
+3.09%
Mar 31, 2025
Jennison Associates LLC
2.49M
5.93%
-7.49K
-0.30%
Mar 31, 2025
Tang Capital Management, LLC
2.45M
5.84%
+200.00K
+8.87%
Mar 31, 2025
Deep Track Capital LP
1.48M
3.53%
+1.48M
--
Mar 31, 2025
The Vanguard Group, Inc.
2.22M
5.28%
+111.43K
+5.28%
Mar 31, 2025
TD Securities, Inc.
1.87M
4.46%
-34.48K
-1.81%
Mar 31, 2025
Morgan Stanley & Co. LLC
1.74M
4.15%
+215.40K
+14.10%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.40M
3.33%
-190.00K
-11.97%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
3.77%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.67%
Invesco Pharmaceuticals ETF
2.62%
Virtus LifeSci Biotech Products ETF
1.91%
ALPS Medical Breakthroughs ETF
1.15%
Harbor Human Capital Factor US Small Cap ETF
0.88%
iShares U.S. Pharmaceuticals ETF
0.78%
First Trust Small Cap Growth AlphaDEX Fund
0.43%
VictoryShares US Small Mid Cap Value Momentum ETF
0.25%
First Trust Small Cap Core Alphadex Fund
0.23%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比3.77%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比2.67%
Invesco Pharmaceuticals ETF
佔比2.62%
Virtus LifeSci Biotech Products ETF
佔比1.91%
ALPS Medical Breakthroughs ETF
佔比1.15%
Harbor Human Capital Factor US Small Cap ETF
佔比0.88%
iShares U.S. Pharmaceuticals ETF
佔比0.78%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.43%
VictoryShares US Small Mid Cap Value Momentum ETF
佔比0.25%
First Trust Small Cap Core Alphadex Fund
佔比0.23%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
